Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper Session 1

187 - A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours


05 Mar 2018


Proffered Paper Session 1


Ruth Plummer


Annals of Oncology (2018) 29 (suppl_3): iii7-iii9. 10.1093/annonc/mdy048


R. Plummer1, S. Halford2, P. Jones2, S. Wedge3, S. Hirschberg2, G. Veal1, G. Payne4, M. Chenard-Poirier4, H. Keun5, U. Banerji6

Author affiliations

  • 1 Newcastle University, NE2 4HH - Newcastleupon Tyne/GB
  • 2 Cancer Research UK Angel Building, London/GB
  • 3 Newcastle University, Newcastle upon Tyne/GB
  • 4 Institute of Cancer Research ICR, London/GB
  • 5 Imperial College London - Hammersmith Hospital, London/GB
  • 6 Drug Development Unit  , The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, SM2 5PT - Sutton/GB


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 187

A key metabolic alteration in tumour cells is increased dependency on glycolysis, resulting in the production of lactate which is transported out of cells by MCTs. Inhibition of MCT-1 can constrain cancer cell growth in preclinical models. We report results on the phase I study of AZD3965, a FIC inhibitor of MCT-1.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings